Abstract:Background Resting heart rate (HR) is a strong established marker of risk in patients with heart failure (HF), but the clinical implications of changes in HR over time are less well established. We aimed to explore the association between visit-to-visit changes in HR and cardiovascular (CV) outcomes in a pooled participant-level dataset of 2 large cohorts of patients with HF across the full range of left ventricular ejection fraction (LVEF). Methods PARADIGM-HF and PARAGON-HF were global, multicenter, randomized clinical trials testing sacubitril/valsartan against an active control (enalapril or valsartan, respectively) in patients with HF and LVEF ≤40% (in PARADIGM-HF) or LVEF ≥45% (in PARAGON-HF). Change in HR was defined as the difference in HR between a visit at any time and the preceding visit. The association between the change in HR and subsequent risk of first HF hospitalization (HFH) or CV death was assessed using Cox proportional hazards models, after adjusting for HR at the preceding visit and potential confounders. HR at any time was also assessed using repeated measures regression models with restricted cubic splines, and was plotted relative to time defined as the number of months prior to or immediately following a HFH event or end of follow-up. Patients who experienced HFH during the study period were compared to a control population who remained free of all-cause hospitalization and all-cause death during the follow-up period. Results A total of 13,194 patients (mean age 67±11 years, 67% men, mean LVEF 40±15%) were included. Heart rates were available in 16 visits in both PARADIGM-HF and PARAGON-HF. Over a median follow-up of 2.4 years, 3,114 patients underwent a first HFH or CV death (10.4 events per 100 patient-years). Any increase in HR from the preceding visit, compared with no change, was associated with a significantly higher risk of first HFH or CV death (Figure 1, adjusted hazard ratio 1.10, 95% confidence interval, CI: 1.08–1.13, P<0.001, per 5 bpm increase in HR). Conversely, a drop in HR was associated with significantly lower risk. This prognostic association between temporal changes of HR and risk of first HFH or CV death was consistent across the range of LVEF (Pinteraction=0.34) and seen irrespective of background use of β-blockers (Pinteraction=0.91). Relative increases in HR were especially prognostic in patients without a history of atrial fibrillation/flutter (Pinteraction=0.01). HR at any time appeared to increase during the 8 months prior to a HFH event, and remained elevated after hospitalization, in comparison to a relatively stable HR observed in the control group (Figure 2). Conclusions Across a broad spectrum of patients with chronic HF, relative increases in HR from a preceding visit strongly and independently predicted both CV and non-CV outcomes. Our findings suggest that detection of notable increases in HR between outpatient visits may help identify patients at heightened risk of adverse events.

The impact of visit‐to‐visit heart rate variability on all‐cause mortality in atrial fibrillation

Longitudinal Association Between Heart Rate at Rest and Mortality in Atrial Fibrillation

Impact of Heart Rate in Atrial Fibrillation Versus Sinus Rhythm on Mortality in Octogenarian Patients with Acute Coronary Syndrome.

Visit-to-visit changes in heart rate in heart failure: a pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials

Heart Rate Variability and Risk of All-Cause Death and Cardiovascular Events in Patients With Cardiovascular Disease: A Meta-Analysis of Cohort Studies

Prognostic Significance of Resting Heart Rate and Use of Β-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients with Heart Failure and Reduced Ejection Fraction

Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the PARADIGM‐HF and PARAGON‐HF trials

Is the Median Hourly Ambulatory Heart Rate Range Helpful in Stratifying Mortality Risk among Newly Diagnosed Atrial Fibrillation Patients?

Long-term association of ultra-short heart rate variability with cardiovascular events

Incidence and impact of atrial fibrillation in heart failure patients: real‐world data in a large community

Heart rate variability and atrial fibrillation in the general population: a longitudinal and Mendelian randomization study

Prognostic value of heart rate variability in atrial fibrillation recurrence following catheter ablation: A systematic review and meta-analysis

Ultra-short heart rate variability over 15 seconds is associated with increased long-term risk of cardiovascular disease

Insight into the relationship between heart rate and mortality in patients in sinus rhythm with heart failure with preserved ejection fraction

Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta‐analysis

Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation

The impact of education level on all-cause mortality in patients with atrial fibrillation

Visit-to-Visit Heart Rate Variability Is Positively Associated With the Risk of Adverse Cardiovascular Outcomes

P3833Low heart rate variability is associated with future arrhythmic events in hypertension

Screening for Atrial Fibrillation (AF) by handheld single-lead ECG and risk of all-cause mortality stratified by non-AF cardiovascular disease

Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction